创伤患者抗凝血酶III水平与结局
这项在一级创伤中心开展的队列研究纳入292例创伤患者,从入院随访至入院后6天,分析抗凝血酶III活性与血栓出血并发症的关联。抗凝血酶III缺乏患者无呼吸机天数(27.8 vs 29.6,P=0.0003)、无住院天数(20.3 vs 24.0,P=1.37×10-6)和无ICU天数(25.7 vs 27.7,P=9.38×10-6)均更少,进展性颅内出血(21.1% vs 6.3%,P=0.0003)和血小板减少(24.8% vs 5.0%,P=1.94×10-6)发生率更高。抗凝血酶III缺乏与深静脉血栓无显著关联,但发生深静脉血栓者抗凝血酶III水平下降更陡且显著低于未发生者。作者认为抗凝血酶III水平可能有助于创伤患者的风险评估。
要点
- 抗凝血酶III缺乏的创伤患者无呼吸机天数更少(27.8 vs 29.6天,P=0.0003)、无住院天数更少(20.3 vs 24.0天,P=1.37×10-6)、无ICU天数更少(25.7 vs 27.7天,P=9.38×10-6)。
- 抗凝血酶III缺乏与进展性颅内出血率更高相关(21.1%[28/133] vs 6.3%[10/159],P=0.0003)。
- 抗凝血酶III缺乏与血小板减少率更高相关(24.8%[33/133] vs 5.0%[8/159],P=1.94×10-6)。
- 抗凝血酶III缺乏与深静脉血栓无显著关联,但发生深静脉血栓者抗凝血酶III水平下降更陡且显著低于未发生者。
- 作者认为,抗凝血酶III水平可能有助于创伤患者的风险评估。
适用人群与场景
- 2015年12月2日至2017年3月24日在一级创伤中心纳入的292例创伤患者,从入院随访至入院后6天。
处置流程与药物剂量
- 血栓预防策略、出血、深静脉血栓和肺栓塞筛查及随访评估按机构方案进行。
研究设计与关键结果
- 队列研究,292例创伤患者,平均(SD)年龄54.4(19.0)岁,男性211例(72.2%)。
- 抗凝血酶III缺乏患者较无缺乏者无呼吸机天数更少(27.8[5.1] vs 29.6[1.4],P=0.0003)、无住院天数更少(20.3[8.2] vs 24.0[5.7],P=1.37×10-6)、无ICU天数更少(25.7[4.9] vs 27.7[2.3],P=9.38×10-6)。
- 抗凝血酶III缺乏与进展性颅内出血率更高相关(21.1%[28/133] vs 6.3%[10/159],P=0.0003),与血小板减少率更高相关(24.8%[33/133] vs 5.0%[8/159],P=1.94×10-6)。
- 抗凝血酶III缺乏与深静脉血栓无显著关联;发生深静脉血栓者抗凝血酶III水平下降更陡且显著低于未发生者。
- 抗凝血酶III缺乏与更重损伤、更多出血和更高死亡率相关,并减少无呼吸机、无住院和无ICU天数。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,抗凝血酶III水平可能有助于创伤患者的风险评估;该研究为关联性研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Patients with trauma exhibit a complex balance of coagulopathy manifested by both bleeding and thrombosis. Antithrombin III is a plasma protein that functions as an important regulator of coagulation. Previous studies have found a high incidence of antithrombin III deficiency among patients with trauma.
OBJECTIVE: To assess whether changes in antithrombin III activity are associated with thrombohemorrhagic complications among patients with trauma.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted from December 2, 2015, to March 24, 2017, at a level I trauma center. A total of 292 patients with trauma were followed up from their arrival through 6 days from admission. Data, including quantification of antithrombin III activity, were collected for these patients. Thromboprophylaxis strategy; hemorrhage, deep vein thrombosis (DVT), and pulmonary embolism screenings; and follow-up evaluations were conducted per institutional protocols. Data analyses were performed from September 28, 2023, to June 4, 2024.
MAIN OUTCOMES AND MEASURES: The primary study outcome measurements were associations between antithrombin III levels and outcomes among patients with trauma, including ventilator-free days, hospital-free days, intensive care unit (ICU)-free days, hemorrhage, venous thromboembolic events, and mortality.
RESULTS: The 292 patients had a mean (SD) age of 54.4 (19.0) years and included 211 men (72.2%). Patients with an antithrombin III deficiency had fewer mean (SD) ventilator-free days (27.8 [5.1] vs 29.6 [1.4]; P = .0003), hospital-free days (20.3 [8.2] vs 24.0 [5.7]; P = 1.37 × 10-6), and ICU-free days (25.7 [4.9] vs 27.7 [2.3]; P = 9.38 × 10-6) compared with patients without a deficiency. Antithrombin III deficiency was also associated with greater rates of progressive intracranial hemorrhage (21.1% [28 of 133] vs 6.3% [10 of 159]; P = .0003) and thrombocytopenia (24.8% [33 of 133] vs 5.0% [8 of 159]; P = 1.94 × 10-6). Although antithrombin III deficiency was not significantly associated with DVT, patients who developed a DVT had a more precipitous decrease in antithrombin III levels that were significantly lower than patients who did not develop a DVT.
CONCLUSIONS AND RELEVANCE: In this cohort study of patients with trauma, antithrombin III deficiency was associated with greater injury severity, increased hemorrhage, and increased mortality, as well as fewer ventilator-free, hospital-free, and ICU-free days. Although this was an associative study, these data suggest that antithrombin III levels may be useful in the risk assessment of patients with trauma.
参考来源
- Farrell DH, McConnell KM, Zilberman-Rudenko J, et al. Antithrombin III Levels and Outcomes Among Patients With Trauma. JAMA Netw Open. 2024. PMID: 39145978. doi:10.1001/jamanetworkopen.2024.27786
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。